Prospective Grant of Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body

Riepilogo

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in the U.S. Patent Applications and Issued Patents listed below to AlleCure Corporation, having a place of business in Chatsworth, California. The patent rights of these inventions have been assigned to the United States of America. USPA 07/330,446 filed March 30, 1989 and entitled "Human Derived Monocyte Attracting Purified Peptide Products Useful in a Method of Treating Infections and Neoplasms in a Human Body and the Cloning of Full Length cDNA Thereof" USPA 07/686,264 filed April 15, 1991 now USPN 6,090,795 issued July 18, 2000 USPA 08/449,552 filed May 24, 1995 now USPN 5,532,144 issued July 2, 1996 USPA 08/466,288 filed June 6, 1995 now USPN 5,714,578 issued February 3, 1998 PCT/US90/00040 filed January 2, 1990 The prospective exclusive license territory will be worldwide and the field of use may be limited to the treatment of asthma, restenosis, hepatitis B and cancer.